Record sales and earnings for Perrigo

ALLEGAN, Mich. (WOOD) - Perrigo Company Tuesday announced its financial report for its fourth fiscal quarter and full fiscal year of 2009, which ended in June.

The Allegan-based business manufactures and markets over-the-counter drugs such as analgesics, cough/cold medicines, antacids, laxatives and nutritional products.

In a statement, the company highlighted these continuing operations for the full year --

• Revenue increased $277 million, or 16 percent, to a record $2 billion
• Adjusted income increased 13 percent to $175 million, or $1.87 per share
• GAAP income increased 1 percent to $141 million, or $1.51 per share
• Record cash flow was $157 million in the fourth quarter and $258 million for the full year

Management expects full-year fiscal 2010 earnings from continuing operations to be in a range of $2 to $2.12 per share, an increase of 7-13 percent compared to adjusted fiscal 2009 EPS.

Perrigo's Chairman and CEO Joseph C. Papa said, "Our team is executing well -- growing market share, managing our supply chain, improving customer service levels, investing in quality and delivering strong returns. By bringing innovative new products to market today and continuing to invest in research and development for future launches, we continue to make quality healthcare more affordable at a time when consumers need to save money more than ever."

On the Net:

Perrigo